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WOODRUTFF AND SYMES (1962a, b) suggested that the increase in spleen and
lymph node weight of A strain mice bearing spontaneous mammary carcinomata
was evidence for the possession of specific antigenicity by these tumours. On
serial passage of the tumour within the strain of origin, the capacity to evoke
splenic and lymph node hyperplasia was lost, and this was attributed to deletion
by the tumour of its specific antigens.
Evidence of increased malignancy accompanying specific antigen deletion was
the occurrence of a lymph node metastasis in one animal bearing a tenth genera-
tion tumour transplant (Woodruff and Symes, 1962b), and the decreased killing
time of tumours in successive transplant generations (Symes, 1965a).
It, nonetheless, seemed desirable to obtain further evidence of a correlation
between the degree of spleen and lymph node hyperplasia and tumour specific
antigenicity. Accordingly, the ability of spleen cells from tumour bearing
animals to transfer adoptive immunity against the tumour to further isogenic
hosts has been investigated.
Koldovsky (1961a) reported success in similar experiments using benzopyrene
induced tumours in A strain mice, where the spleen and lymph nodes were also
hyperplastic. However Prehn (1960) had previously been unable to transfer
adoptive immunity against dibenzanthracene induced fibrosarcomas. Moreover
carcinogen induced tumours in mice have, in general, been found to show more
evidence of specific antigenicity than " spontaneously occurring " neoplasms
(Foley, 1953a, b; Revesz, 1960; Koldovsky, 1961b).
Recently Woodruffand Boak (1966) have demonstrated a significant inhibition
of tumour growth in both methylcholanthrene induced mouse sarcomata and
spontaneous mouse mammary carcinomata, transplanted to isogenic hosts treated
with the reticulo-endothelial system stimulant, Corynebacterium parvum. This
effect was obtained whether the bacteria were injected either shortly before or
after tumour transplantation, and would seem to be strong evidence for the
possession of specific antigens by both types of tumour.
MATERIALS AND METHODS
General plan of the experiments
For each tumour to be studied the prospective A strain (isogenic) hosts were
divided into three groups.
Animals in the first group received, immediately before tumour transplantation,ADOPTIVE IMMUNITY AND MOUSE CARCINOMATA
an intravenous injection of 30 million spleen cells from the animal bearing the
tumour. Animals in the second group received a similar injection of 30 million
spleen cells from a normal A strain mouse. Donor and host animals were either
of the same sex or, if of the opposite sex, female spleen cells were always injected
into male recipients. The third group of animals received no spleen cells.
Later on the same day all the animals in each group received a subcutaneous
transplant, of equal size, from the tumour being studied.
The rates of tumour growth and times of death were compared between the
three groups of animals bearing transplants of a given tumour.
¢ice and tumours studied
Highly inbred A strain mice of both sexes, maintained in this department by
strict brother x sister mating, have been used throughout. For a given tumour
the animals used were all of the same sex, or the sexes were evenly balanced in
the several groups.
Six different A strain mammary carcinomata were studied. Five, numbers
1-5 (Table I), were obtained from the female mouse in which they had arisen.
Two specimens of tumour 6 were used, one having previously been passaged ten
times and the other twelve times, at intervals oftwo to four weeks in the A strain.
Observations on animals bearing tumours
Tumour donors.-Before transplantation the diameter of each tumour was
measured to the nearest millimetre with a caliper, in two planes at right angles
to each other, the result being expressed as a mean diameter.
Each tumour bearing animal was weighed to the nearest 0.1 g. The spleen,
thymus and inguinal and axillary lymph nodes were removed, weighed to the
nearest 0.1 mg., and the results expressed as in Symes (1965b).
Tumour recipients.-The diameter of each tumour was measured, at intervals
of 5-7 days, as described above.
The day of death of each animal was also noted.
RESULTS
Symes (1965b) postulated that the immunological response of the host to the
specific antigens of a given subcutaneous tumour follows a regular cycle, as the
antigens are deleted during progressive tumour growth. Firstly there is hyper-
plasia of the axillary and inguinal lymph nodes, both ipsilateral and contralateral
with reference to the tumour site. Then, as the lymph nodes are returning to
their normal weight, hyperplasia of the spleen commences and is for a time
progressive. Finally the spleen weight returns to normal, and by this time the
lymph nodes have become grossly hypoplastic.
Data for the relative spleen weights, and ipsilateral and contralateral lymph
node weights, from each of the six tumours are given in Table I. The tumours
may be divided into three categories according to their degree ofspecific antigeni-
city. The first category comprises tumours 1 and 2. Here there is a marked
lymph node hyperplasia especially in the case of tumour 1, whilst the relative
spleen weight is near normal for tumour 1, and markedly increased in the case
of tumour 2. Tumours 3, 4 and 5 form the second category in which the lymph
nodes have either returned to normal size or become hypoplastic, whilst the
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TABLE I.-Tumnour Size, and Host Relative Spleen, Thymic and Lymnph
Node Weights, for Each of the Several A Strain Tumours Studied
Tumour Host
, -- - A- -~
Weight of lymph nodes
Number of times Size on Relative Weight of -
Tumour previously transplantation spleen thymus Ipsilateral Contralateral
number passaged (mm.) weight* (mg.) (mg.) (mg.)
1 Spontaneous 14-0 7-57 21-0 36-9 47-0
2 Spontaneous 17-5 12-75 15-8 35-2 28-0
3 Spontaneous 24-0 9-05 10-2 18-3
4 Spontaneous 14-5 . 9-72 16-6 235- 185-
5 Spontaneous 17-0 561 9-5 11-5 8-5
6f(a) 10 . 5-14 5,8 15-0 13-0
\(b) 12 15-5 * 603 23-0 6-8 4-5
Relative spleen weight Weight of spleen mg Weight of mouse g.
Data for the relative spleen and lymph node weights from ten normal adult A strain female niiee
were as follows: (Woodruff and Symes, 1962b).
Relative spleen weight 6- 10 ± 0 94.
Weight of lymph nodes on the right side (corresponding to ipsilateral) 23- 9 4 4- 92 mg.
Weight of lymph nodes on the left side (corresponding to contralateral) 22 7 ± 4- 58 mg.
The corresponding values for male mice are similar.
relative spleen weights remain elevated, except in the case of tumour 5. The
third category comprises the tenth and twelfth transplant generations oftumour 6,
where the nodes are hypoplastic and the relative spleen weights within normal
limits.
It is of interest to note that the thymic weights show no correlation with the
above scheme.
In Table II are recorded the survival times of animals bearing transplants
from the six tumours studied.
For a given tumour there is a close correlation between its category, described
above, and the degree of adoptive immunity transferred following the injection of
spleen cells from the tumour donor into the tumour recipient.
In the case of the first category, tumours 1 and 2, spleen cells from tumour
donor 1 caused a significant increase in the survival time of the tumour recipients
when compared with the animals receiving normal isogenic spleen cells, or no
spleen cells, t 2*307, n - 8, p < 0-05, whilst spleen cells from tumour donor 2,
although not so effective, caused an appreciable increase in the survival time
in two out of four recipients.
Spleen cells from tumour donors of the second category, tumours 3, 4, and 5,
did not influence the survival time of tumour recipients in comparison with the
effect of normal isogenic cells, survival in both cases being similar to that of
uninjected animals.
In the case of tumour 6, injection of spleen cells from the tumour donor signi-
ficantly shortened the survival of tumour recipients in comparison with the un-
injected animals, t = 4.31, n = 9, p = 0.01. A similar effect was seen in the
case of animals receiving normal isogenic cells, t- 410, n = 8, p < 0.01. There
was, however, no significant difference in the survival of tumour recipients when
comparison was made between the prior injection of tumour donor or normal
isogenic spleen cells, t - 1.48, n -9, p < 0-2 > 0 1.
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TABLE II.-Survival Times of A Strain Mice Receiving Subcutaneous A Strain
Mammary Carcinoma Transplants on Day 0
Immediately before tumour transplantation some of the mice received an
intravenous injection of 30 million spleen cells (T) from the mouse bearing
the donor tumour, and others a similar injection of spleen cells (N) from a
normal A strain mouse.
Day of death
Tumour Type of spleen Number of
Number* cells injected observations Individual values Mean
1 T . 4 . 76 67 74; 76 73- 0
N . 3 . 72; 47; 51 56-7
Nil 3 . 74; 55; 39 56- 0
2 . T . 4 33; 58; 159; 47 74-3
N . 4 . 47; 48; 47; 47 47.3
Nil . 3 . 27; 40; 47 38-0
3 . T . 4 48; 54; 41; 45 47- 0
N . 2 . 48; 39 43- 5
Nil . 3 . 38; 34; 49 40 3
4 . T . 4 . 83; 67; 60; 71 70* 3
N . 3 . 29; 32; 71 44- 0
Nil . 3 . 71; 71; 71 71-0
5 . Tt . 2 . 58; 67 62-5
Nt . 2 . 82; 63 72-5
Nil . 3 . 68; 54; 61 61-0
6 (a) and (b) * T . 6 . 39; 23; 34; 40; 26; 37 33 0
N . 5 . 46; 39; 35; 38; 35 38- 6
Nil * 5 . 46; 48; 48; 45; 48 47 - 0
* The tumours are numbered as in Table I.
t Received 50 million spleen cells intravenously.
For a given tumour the growth rate in tumour recipients was uninfluenced
by the prior injection of spleen cells.
DISCUSSION
In the case of tumour 1, which retained the greatest degree of specific anti-
genicity, spleen cells from the spontaneous tumour bearing mouse were able to
transfer adoptive immunity to the isogenic tumour recipients.
A similar, but less marked effect was seen with the slightly more advanced
tumour, number 2. Thus confirmation is provided for the hypothesis ofWoodruff
and Symes (1962a, b) that the splenic and lymph node hyperplasia of tumour
bearing mice is an immunological response to the presence of tumour specific
antigens.
The weakness of the transferred immunity, measured in retardation oftumour
growth rather than resistance thereto, is almost certainly a reflection of the weak
immunising power of tumour specific antigens.
That decline in the host spleen and lymph node weight is a sign of specific
antigen deletion by the tumour also finds confirmation in the above results (see
tumours 3, 4 and 5). It may be noted that the results for tumour 5 do not differ
from those for tumours 3 and 4, despite the injection of 50 million spleen cells in
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Theoretically, in the case of tumour 6, spleen cells from the tumour donor
should be similar, in terms of anti-tumour immunity, to normal spleen cells; thus.
a similar effect of both on the survival of tumour recipients would be expected.
That both classes of spleen cells produce a significant shortening of survival
would suggest that they may act synergistically with the tumour cells. Thus.
injection of spleen cells devoid of any anti-tumour immunity may approximate to
transplanting a larger tumour.
The behaviour of a transplant of isogenic spleen cells is similar to that of a
tumour in that the spleen cells actively proliferate and metastasise. It is therefore
possible that the response ofthe body to these challenges is similar, with a resultant
deflection of. and decrease in resistance to, the tumour.
SUMMARY
A given spontaneous or repeatedly transplanted A strain mammary carcinoma
was transplanted subcutaneously to a number of isogenic hosts.
Immediately beforehand some of the hosts had received an intravenous injec-
tion of 30 million spleen cells from the tumour donor, others 30 million normal
A strain spleen cells, and the third group were uninjected.
In the case of the spontaneous tumour with the most specific antigenicity it
was possible to transfer adoptive immunity against the tumour with spleen cells
from the tumour donor.
In the case of the much passaged tumours, both of which had deleted their
specific antigens, spleen cells from the tumour donor and normal isogenic spleen
cells shortened the life ofthe tumour recipients; this is attributed to a synergistic
effect of the spleen and tumour cells.
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